In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Phase II Alliances Command the Most Interest

Executive Summary

Biotechs have always relied on four sources of financing: venture capital, public equity, M&A, and alliances. But of these four financing "legs", only one remains strong: alliances. There's no question that average potential deal values-a combination of up-front fees and pre-commercialization money-are increasing nicely. But while the mean value of early-stage deals has remained steady, deal values for both Phase II and Phase III /NDA-stage compounds have continued to climb.

You may also be interested in...

Pharmaceutical Strategic Outlook: The Trouble with Alliances

At Windhover's March 2008 Pharmaceutical Strategic Outlook meeting one overriding theme was an alliance paradox: values continue to rise and deals provide an increasingly important source of funds for biotechs, yet public investors don't seem to like these deals. Plus: a discussion of big-pharma outlicensing and the importance of CFOs in pharma strategy.

The Value of Proof-Of-Concept

Big Pharma's unprecedented spending levels in licensing continue. But some recent deals suggest the real linchpin of licensing value is proof-of-concept in humans.

UK Government Wants To Work With Industry To Identify OTC Switch Candidates

The UK's medicines regulator, MHRA, alongside other government agencies, intends to work together with manufacturers to identify Rx-to-OTC switch candidates. Switch criteria might include “different strength medicines to those available today, combination formulations, or medicines manufacturers already offer without prescriptions in other countries,” NHS England says, in its recently published “Delivery plan for recovering access to primary care.”

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts